Approaches to Personalized Treatment for CLL: Expert Guidance on Sequencing Therapy and Novel Agents

Approaches to Personalized Treatment for CLL: Expert Guidance on Sequencing Therapy and Novel Agents (December 2019)

Friday, December 6, 2019
Breakfast -- 7:30 AM ET

Agenda

Welcome, Introduction, and Baseline Assessment

Talk 1 Overview of CLL Diagnosis, Evaluation, and Novel Targeted Agents

Talk 2 Selecting Therapy for Treatment-Naive CLL/SLL

Talk 3 Considerations in Selecting Therapy for Previously Treated CLL

Talk 4 Near Future Directions: Promising Agents and Combinations Under Investigation

Clinical Trial Spotlight highlighting key ongoing studies as well as a preview of studies to be presented at ASH 2019

Summary, Final Thoughts, Posteducation Assessment, and Audience Question and Answer Session

Faculty

Program Director
William Wierda, MD, PhD

Professor of Medicine
Chief, Section of CLL
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Faculty
Asher Chanan-Khan, MD

Chair, Department of Hematology/Oncology
Mayo Clinic
Jacksonville, Florida

Faculty
Thomas J. Kipps, MD, PhD

Evelyn and Edwin Tasch Chair in Cancer Research
Distinguished Professor of Medicine and Deputy Director,
Research Operations
University of California, San Diego
Moores Cancer Center
La Jolla, California

Faculty
Anthony Mato, MD, MSCE

Hematologic Oncologist
Director,
CLL Program
Memorial Sloan Kettering Cancer Center
New York, New York

Goal Statement
The goal of this activity is to improve the knowledge and competence of clinicians to implement best practices in the treatment of CLL.

Target Audience 
This program is intended for physicians, nurses, pharmacists, physician assistants, and other healthcare providers who treat and manage patients with chronic lymphocytic leukemia.

Learning Objectives

  • Consider efficacy and safety profile of the therapeutic agent along with patient characteristics and molecular features of CLL to individualize therapeutic strategies for newly diagnosed CLL
  • Choose optimal treatment for relapsed/refractory CLL based on the available clinical data, guidelines, and expert recommendations
  • Plan treatment strategies that sequence targeted agents to optimize patient outcomes and quality of life
  • Evaluate promising approved and investigational agents and combination regimens in CLL, including efficacy, unique toxicities, and other practical management considerations
  • Manage adverse events associated with treatment approaches for CLL to ensure treatment compliance as well as improved clinical outcomes and quality of life

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
NCCN designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
NCCN designates this educational activity for a maximum of 3.0 contact hours.

Pharmacist Continuing Education

NCCN designates this application-based continuing education activity for 3.0 contact hour (0.3 CEUs) of continuing education credit. UAN: JA4008196-9999-19-071-L01-P.

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 3.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Attention Pharmacists:
You must complete the post-test and evaluation within 30 days of the activity. Continuing pharmacy education credit is reported to the CPE Monitor once the post-test and evaluation are completed. Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth or your credit cannot be reported. If you have not already done so, please complete your e-profile at https://nabp.pharmacy/ to obtain your NABP e-Profile ID.

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). Full disclosure of faculty relationships will be made prior to the activity. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.